Patent foramen ovale closure

Jennifer Franke, Nina Wunderlich, Stefan C Bertog, Horst Sievert

Research output: Chapter in Book/Report/Conference proceedingChapter

1 Scopus citations

Abstract

A patent foramen ovale (PFO) is quite common and persists in approximately 20–30% of adults. In combination with predisposing morphologic and hemodynamic conditions, this remnant interatrial communication promotes thromboembolic events, most notably cerebrovascular events. Feasible treatment strategies include antithrombotic medication (antiplatelet therapy or anticoagulation), surgery, or transcatheter defect closure. Though to date no randomized trials exist showing that medical therapy versus placebo in any patient population with cryptogenic stroke is truly effective in preventing recurrent events, current guidelines promote medical therapy over endovascular or surgical PFO closure as a first-line therapy in patients with cryptogenic stroke and a PFO. This chapter reviews the pathophysiology of presumed paradoxical embolism through a PFO, current guidelines, the history and current status of device technology, and critical aspects to consider when facing a residual shunt after transcatheter PFO closure.

Original languageEnglish (US)
Title of host publicationCatheter-Based Cardiovascular Interventions
Subtitle of host publicationA Knowledge-Based Approach
PublisherSpringer Berlin Heidelberg
Pages679-685
Number of pages7
ISBN (Electronic)9783642276767
ISBN (Print)9783642276750
DOIs
StatePublished - Jan 1 2013

Fingerprint

Dive into the research topics of 'Patent foramen ovale closure'. Together they form a unique fingerprint.

Cite this